Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.

Inclusion Criteria: * patients with choroidal neo-vascularization (CNV) as a consequence of age-related macular degeneration (AMD) * age 50 and older, male and female * membrane \<= 12 papillary diameter * visual acuity between 20/320 and 20/40 (ETDRS) * written informed consent Exclusion Criteria: * known hypersensitivity to the medicinal product under investigation, ingredients or medicinal products with a similar chemical structure * participation in another clinical trial within the last 4 weeks * unability to understand trial information * pregnant or lactating women * women with an amenorrhea \< 12 months * suspected unability to cooperate * detachment of pigment epithelium without membrane detection \>= 50%,retinal angiomatotic proliferation (RAP), presumed ocular histoplasmosis syndrome (POHS), chorioretinal anastomosis (CRA), myopic CNV, CNV following trauma, uveitis, RCS or reasons except AMD * rupture of pigment epithelium * sub-retinal bleeding \>= 50% of membrane or \>= 1 PD * sub-retinal fibrosis or chorio-atrophy * pre-treatment with Verteporfin (photodynamic therapy), radiotherapy, trans-pupillary thermotherapy of the eye under investigation as a consequence of maculadegeneration treatment with Verteporfin of the eye not under investigation within 7 days prior inclusion * former participation in clinical trials with anti-angiogenic substances: Pegaptanib, Ranibizumab, Bevacizumab, Anecortave Acetat, Proteinkinase C Inhibitors * former injection of anti-angiogenic substances in the eye under investigation * former focal sub-foveal lasercoagulation of the eye under investigation * juxta- or extra-foveal lasercoagulation of the eye under investigation within 1 month prior inclusion * former vitrectomy * former surgery as a consequence of maculadegeneration * glaucoma patients which have been treated with prostaglandin containing eye drops * other ocular diseases which may lead to surgery within the clinical study or may lead to a loss of vision of two lines * acute intraocular inflammation of the eye under investigation * vitreous hemorrhage of the eye under investigation * macula-foramen of the eye under investigation * diabetic retinopathy * former retina detachment of the eye under investigation * uveitis * acute conjunctivitis, keratitis, scleritis, or endophthalmitis * aphakia or pseudo-aphakia with damaged back-capsule(exception: YAG-capsulotomy) * myopia larger than -8 diopter * former intra-ocular surgery of the eye under investigation within 2 months prior inclusion * de-compensated glaucoma with \>= 30 mm Hg despite therapy * former filtrating glaucoma surgery of the eye under investigation * former corneal grafting of the eye under investigation * former stroke or heart attack * on-going therapy because of systemic infection * known allergic reaction to fluorescein * bad quality of fundus documentation because of bad range of vision